Related Experiment Video
Updated: Jun 4, 2026
16:07
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Tocilizumab: is there life beyond anti-TNF blockade?
J D Alves1, A Marinho, M J Serra
1Department of Medicine IV, Fernando da Fonseca Hospital, Lisbon, Portugal. jose.alves@fcm.unl.pt
International Journal of Clinical Practice
|January 29, 2011
Summary
Anti-tumor necrosis factor-alpha (TNF-α) therapy is effective for rheumatoid arthritis, but 30% of patients show poor response. Interleukin-6 (IL-6) targeting with tocilizumab offers an alternative approach for rheumatoid arthritis treatment.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Anti-tumor necrosis factor-alpha (TNF-α) therapy is a primary biological treatment for rheumatoid arthritis (RA).
- Despite its efficacy, approximately 30% of RA patients exhibit an inadequate response to anti-TNF-α agents.
- This limitation necessitates the exploration of alternative therapeutic targets and strategies for RA management.
Purpose of the Study:
- To evaluate interleukin-6 (IL-6) as an alternative therapeutic target in rheumatoid arthritis.
- To compare the clinical advantages of tocilizumab, an anti-IL-6 soluble receptor antibody, against anti-TNF-α therapies.
Main Methods:
- Review of clinical trial data for tocilizumab in rheumatoid arthritis patients.
- Comparative analysis of treatment outcomes between IL-6 inhibition and anti-TNF-α therapy.
Main Results:
- Tocilizumab demonstrates potential advantages in addressing specific clinical aspects of RA not fully managed by anti-TNF-α therapy.
- IL-6 blockade represents a viable alternative treatment pathway for non-responders to anti-TNF-α therapy.
Conclusions:
- Interleukin-6 (IL-6) inhibition, exemplified by tocilizumab, offers a promising alternative for rheumatoid arthritis patients with suboptimal responses to anti-TNF-α treatments.
- Targeting IL-6 addresses unmet needs in RA management, complementing existing anti-TNF-α strategies.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...